Rocket Pharmaceuticals Inc (RCKT)
18.46
+0.86
(+4.89%)
USD |
NASDAQ |
Sep 27, 16:00
18.46
0.00 (0.00%)
After-Hours: 20:00
Rocket Pharmaceuticals SG&A Expense (Annual): 73.32M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 73.32M |
| December 31, 2022 | 58.77M |
| December 31, 2021 | 41.77M |
| December 31, 2020 | 28.86M |
| December 31, 2019 | 18.24M |
| December 31, 2018 | 17.89M |
| Date | Value |
|---|---|
| December 31, 2017 | 12.54M |
| December 31, 2016 | 9.894M |
| December 31, 2015 | 7.842M |
| December 31, 2014 | 2.112M |
| December 31, 2013 | 1.324M |
| December 31, 2012 | 2.307M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
18.24M
Minimum
2019
73.32M
Maximum
2023
44.19M
Average
41.77M
Median
2021
SG&A Expense (Annual) Benchmarks
| Apellis Pharmaceuticals Inc | 500.82M |
| Arcutis Biotherapeutics Inc | 185.14M |
| NovaBay Pharmaceuticals Inc | 12.83M |
| Palatin Technologies Inc | 15.29M |
| iBio Inc | 11.67M |